Trial Profile
A prospective, randomized, double dummy, double blind, multi-center trial comparing the safety and efficacy of moxifloxacin 400 mg IV QD 24 hours to that of ertapenem 1.0 g IV QD 24 hours for 5 to 14 days for the treatment of subjects with complicated intra-abdominal infections (PROMISE Study).
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Moxifloxacin (Primary) ; Ertapenem
- Indications Bacteroides infections; Escherichia coli infections; Intra-abdominal infections; Streptococcal infections
- Focus Registrational; Therapeutic Use
- Acronyms PROMISE
- Sponsors Bayer
- 15 Jun 2019 Trial has been completed in Spain.
- 02 Aug 2011 New source identifed and integrated (European Clinical Trials Database).
- 13 Sep 2010 Primary endpoint results (n=573) presented at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy